Oral GLP-1 · Foundayo · FDA-approved 2026
Orforglipron
Orforglipron, sold as Foundayo, is a once-daily GLP-1 pill the FDA approved in April 2026 for weight loss. What sets it apart is how easy it is to take: one tablet, any time of day, with or without food, no water rule and no waiting. It does not take off as much weight as the injections do. Dr. Eduardo will tell you straight whether that trade makes sense for you.
Medically reviewed by Dr. Roger Eduardo, MD, FASMBS
Last reviewed: August 2026
FDA labeling checked: August 2026
FDA Prescribing InformationMedically reviewed by Dr. Roger Eduardo, MD, FASMBS, Board-Certified General Surgeon. Last reviewed August 2026.
Book a consultation →FDA-approved use
What Orforglipron is approved for
FDA-approved (April 1, 2026) for long-term weight management in adults with obesity, or overweight with at least one weight-related condition, alongside diet and activity changes. It is not approved to treat type 2 diabetes. It should not be taken with another GLP-1 medication.
The essentials
Orforglipron, at a glance.
How it works
A GLP-1, in a pill
It works on the same appetite pathway as the GLP-1 injections: you feel full sooner and stay full longer. Unlike them, it survives digestion, so it can be an ordinary tablet.
How it's taken
Daily, on your schedule
One tablet a day, any time, with or without food. You start at a low dose and step up no faster than once a month, up to a maximum of 17.2 mg.
Who qualifies
BMI 30+, or 27+ with a condition
Adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition, after a medical evaluation. Not for anyone with a history of medullary thyroid cancer or MEN2, or during pregnancy.
Expected results
About 11% body-weight loss, on average.
In the ATTAIN-1 trial, adults with obesity or overweight and without diabetes lost on average about 11.1% of their body weight over 72 weeks on the highest dose, against about 2.1% for those on a placebo. Roughly 36% lost 15% or more. That is less than the injections average, and it is the honest trade for taking a pill.
Source: ATTAIN-1 (Wharton et al., N Engl J Med 2025) and the FDA prescribing information for Foundayo (April 2026). Trial figures are averages across a large group, not a promise of your own result.
In real life Trial averages assume you reach a full dose and stay on it. Most people don’t: in a 7,881-patient study, real-world weight loss at one year averaged 8.7% overall — about 3.6% for people who stopped within three months, against 11.9% for those who stayed on treatment, with more than 80% never reaching a full maintenance dose. That gap is titration, side-effect management and follow-up, which is exactly what a structured, supervised program is for. Gasoyan H, et al. Obesity, 2025.
average body-weight loss at 72 weeks on the maximum 17.2 mg dose (ATTAIN-1)
Once-daily tablet, any time of day, with or without food
In depth
Everything you need to decide.
A plain-English walkthrough of what Orforglipron is, who it is for, how it is dosed, and what it costs, so your visit starts with questions, not confusion.
What it is, in plain terms
Foundayo is a GLP-1, the same family of medication as Wegovy and Zepbound. The difference is that those have to be injected, because the medicine in them would be broken down by your stomach if you swallowed it. Foundayo is built differently, so it works as an ordinary tablet.
It is not the first GLP-1 pill for weight loss. Wegovy tablets arrived a few months earlier. What is unique to Foundayo is that there are no rules attached to taking it: no empty stomach, no measured sip of water, no waiting half an hour before breakfast.
It is a branded, FDA-approved medicine, not a compounded copy, and we supervise it exactly the way we supervise the injections.
Who it actually suits
The people for whom a pill genuinely changes the decision are those who will not do needles, and those whose week is too unpredictable to rely on a weekly injection. If that is you, this is a real option rather than a consolation prize.
If it is not you, the injections take off more weight on average, and we will say so rather than sell you the more convenient thing.
It is not used together with another GLP-1, not during pregnancy, and not if you have a personal or family history of medullary thyroid cancer or MEN2. Everyone starts with a medical evaluation.
Dosing, and what it costs
You start at the lowest dose and move up one step at a time, staying at least a month at each step, to a maximum of 17.2 mg a day. That slow climb is the whole trick to tolerating it: rushing it is what makes people feel sick and quit. If you miss a week or more, we restart lower rather than picking up where you left off. (If you have read about a 36 mg dose in the news, that was a research dose used in the studies. It is not a strength anyone is prescribed.)
Coverage for a brand-new medication is still settling and varies a lot by plan, so we check your specific benefits before you start instead of quoting a number that will be out of date next month. Eli Lilly publishes current self-pay and savings pricing, and we will point you to today's figure.
Self-pay pricing
Current cash pricing, straight from the source
If your insurance does not cover Orforglipron, the manufacturer publishes current self-pay pricing through LillyDirect. Because pricing changes over time, we link you to the official figure rather than quote one that could go stale. We verify your coverage first and explain your options, including financing through Cherry.
Side effects & safety
What to expect, and how we manage it.
Most side effects are gastrointestinal and mildest at the starting dose. We titrate slowly, coach smaller protein-forward meals and hydration, and adjust if needed. That is the advantage of physician supervision.
- Most common Stomach related, and worst while the dose is climbing. On the maximum 17.2 mg dose in the trials: nausea about 35%, diarrhea 25%, vomiting 24%, constipation 24%, indigestion 13%. Most of it was mild to moderate and settled as people stayed on a dose.
- Managing it Go up slowly, hold each step a full month, eat smaller protein-forward meals, drink plenty of water, and stay away from greasy or heavy food. Most people who climb slowly get through it.
- How many stop About 8 in 100 people stopped because of side effects, against 3 in 100 on a placebo. Worth knowing up front rather than finding out at week six.
- Rare but serious Pancreatitis, gallbladder problems, kidney injury from dehydration and severe stomach reactions are uncommon but real. Stop taking it and call us for severe or persistent abdominal pain.
- Boxed warning Boxed warning: in rodent studies, GLP-1 medicines in this class caused thyroid C-cell tumors. It is not known whether this applies to humans. These medications are contraindicated if you have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
- Before surgery or sedation Tell your surgeon and anesthesiologist you take this medication before any procedure that requires sedation. GLP-1 medicines slow stomach emptying, so your fasting instructions may need to change to lower the risk of aspiration.
- Other medicines you take Bring us your full list, because a few common ones matter. Some medications cap how high your dose can go, and simvastatin in particular has a specific dose limit with Foundayo. The important one is birth control: the pill may not work reliably while you are on this, so use a non-pill method or add a barrier method for 30 days after you start and for 30 days after every dose increase. It is not recommended if you have severe liver disease.
- Not for Taking alongside another GLP-1; a personal or family history of medullary thyroid cancer or MEN2; pregnancy; or a previous serious allergic reaction to Foundayo, orforglipron or one of its ingredients.
Before you start
Foundayo interacts with more everyday medicines than the injections do.
The injectable GLP-1s largely pass your liver by. Foundayo is handled by the same liver pathway that processes a lot of common prescriptions, so it can affect them and they can affect it. Bring your whole medication list to your visit, including anything you only take now and then.
Birth control pills
Foundayo can make birth-control pills less effective. Use a non-oral method, or add a barrier method, for 30 days after starting and for 30 days after each dose increase.
Some medicines cap your dose
Some common prescriptions, including certain antibiotics, antifungals and heart medications, mean your Foundayo dose has to stay at or below 9 mg a day. A few others make it work less well and are avoided. This is why we go through your list properly.
Cholesterol medicine and liver
If you take simvastatin, it needs to stay at 20 mg a day or lower while you are on Foundayo. Foundayo is not recommended if you have severe liver disease.
Source: FDA prescribing information for Foundayo (orforglipron), April 2026. Read the label.
The other GLP-1 pill
Wegovy tablets (oral semaglutide)
Wegovy tablets take off more weight on average, about 14% over 64 weeks, but have to be taken on an empty stomach with a 30-minute wait before anything else. Foundayo trades some of that result for a pill you can take whenever.
See Wegovy tablets (oral semaglutide) →Go deeper
The medical weight-loss program
The full clinical page on how this medicine works, candidacy, results and side effects.
Learn more →Compare
Semaglutide vs. tirzepatide
Which GLP-1 fits you: how the two injectables compare on results, dosing, side effects and cost.
Compare them →See also all the medications we prescribe and the full medical weight-loss program. Omnia Health prescribes branded, FDA-approved medications only, never compounded.
Both pills, plainly
There are two GLP-1 pills. Here is the difference.
Until recently every GLP-1 for weight loss was an injection. Two are now tablets. They are not interchangeable, and the right one usually comes down to your morning, not your biology.
| Attribute | Foundayo orforglipron · you are here | Wegovy tablets oral semaglutide 25 mg |
|---|---|---|
| What it is | A newer medicine, built from the start to survive digestion | The same medicine as the Wegovy injection, in tablet form |
| FDA-approved | April 2026, weight management | December 2025, weight management and cardiovascular risk reduction |
| How you take it | One tablet a day, any time, with or without food, no water rule | One tablet on waking, empty stomach, up to 4 oz water, then nothing for 30 minutes |
| Average weight loss in trials | About 11% at 72 weeks | About 14% at 64 weeks |
| Best suited to | People who want a pill with no routine to protect | People who can reliably protect a 30-minute window each morning |
Trial averages, not a promise of your result. Sources: ATTAIN-1 and the FDA label for Foundayo; OASIS 4 for oral semaglutide 25 mg. Neither pill should be combined with another GLP-1.
Orforglipron FAQ
Orforglipron questions
Can't find your answer here? Call us at (470) 742-1832 or book a consultation, we'll answer every question before you commit to anything.
Yes. The FDA approved orforglipron, sold as Foundayo, on April 1, 2026 for long-term weight management in adults with obesity, or overweight with a weight-related condition. It is not approved to treat type 2 diabetes.
In the trial that led to approval, adults on the highest dose lost on average about 11% of their body weight over 72 weeks, and roughly a third lost 15% or more. Those are averages across a large group, not a promise. What you get depends on your dose, how long you stay on it, and what else is in your plan.
On average, no. Foundayo's roughly 11% compares with about 15% for injectable semaglutide and about 21% for tirzepatide. There has never been a head-to-head trial, so that comparison is across separate studies, but the direction is clear. The pill's advantage is convenience, not results.
One tablet a day, any time of day, with or without food, and no waiting before you eat or drink. That is the whole routine, and it is the main reason to choose it over the other pill.
You start low and step up about once a month to a maximum of 17.2 mg a day. If you have read about a 36 mg dose in news coverage, that was a research dose used in the studies and is not a strength you can be prescribed.
No. Foundayo is a branded, FDA-approved medication. Omnia Health prescribes only FDA-approved, branded medications, never compounded GLP-1s.
Start your journey
See if Orforglipron is right for you.
Book a medical evaluation with Dr. Eduardo, and get a plan, not just a prescription.
